Yishengtai (beinaglutide) / Shanghai Benemae Pharma - LARVOL DELTA

Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review. (PubMed, Int J Mol Sci) - "The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide. GLP-1 receptor agonists show promising liver-related benefits in NAFLD and MASH, particularly in obesity, type 2 diabetes, or earlier-stage disease. Their effects on advanced fibrosis and long-term outcomes remain uncertain, warranting larger, longer-term studies."

Journal • Review • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

The effect of beinaglutide on visceral fat and body weight in obese type 2 diabetic patients. (PubMed, Arch Med Sci) - "A lack of GLP-1 might be responsible for the onset of obesity in patients with T2DM. T2DM and obesity are related not only to insulin deficiency/insulin resistance but also to GLP-1 deficiency, which may cause obesity in patients with T2DM."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists and the Gut Microbiome in Obesity: A PRISMA-Guided Integrative Review of Human Clinical Evidence (ECO 2026) - "Beinaglutide was associated with restoration of alpha diversity and enrichment of metabolically favorable genera (including Blautia and Gemmiger) with reductions in taxa linked to inflammation (including Prevotella, Lachnospira, and Dialister), without changes in beta diversity. In obesity with polycystic ovary syndrome, exenatide combined with metformin promoted taxonomic and functional remodeling, increasing short-chain fatty acid producing genera (including Blautia and Faecalibacterium) and downregulating inflammatory pathways, without changes in overall diversity. In obesity-associated type 2 diabetes mellitus, dulaglutide combined with probiotic supplementation increased Lactobacillus and Bifidobacterium (p<0.001) and reduced Enterococcus and Escherichia coli compared with dulaglutide alone (all p<0.001), although attribution to GLP-1 RA alone was limited... GLP-1 RAs are associated with favorable compositional and functional modulation of the gut microbiota..."

Clinical • Review • Diabetes • Genetic Disorders • Inflammation • Obesity • Polyendocrine Metabolic Ovarian Syndrome • Type 2 Diabetes Mellitus

Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review. (PubMed, Obes Rev) - "Acute or chronic GLP-1RA monotherapy does not appear to impact EE independent of weight loss. Combining GLP-1RA with glucagon or GIP may impact EE in different ways, requiring further exploration."

Journal • Review • Genetic Disorders • Obesity

Outcomes of Beinaglutide on Weight Loss in Patients With Diabetes or Obesity: A Systematic Review and Meta-Analysis. (PubMed, Cureus) - "Nine studies (six randomized controlled trials, two prospective cohort studies, and one retrospective cohort study), comparing beinaglutide with other therapies such as metformin, insulin glargine, and lifestyle modifications, were included. Beinaglutide demonstrated greater weight loss compared to placebo or active comparators but was associated with higher rates of AEs. Further long-term and comparative studies are needed to clarify its safety profile and potential advantages over current treatments."

Journal • Retrospective data • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Obesity in China: current progress and future prospects. (PubMed, Lancet Diabetes Endocrinol) - "Since 2021, five additional GLP-1 receptor agonists (including liraglutide, beinaglutide, semaglutide, tirzepatide, and mazdutide) have been approved in China for weight management, broadening therapeutic choices and initiating a transformation in obesity care. These include limitations in existing diagnostic criteria for obesity which captures phenotypic and cardiometabolic heterogeneity; limited availability of quantifiable, actionable, and accountable national targets which weakens governance and evaluation; and a scarcity of evidence-based algorithms for obesity pharmacotherapy, which risks over-reliance on medication and diverts attention from socioeconomic, environmental, and behavioural determinants. We call for people-centred, integrated systems that embed whole-person obesity care within a planetary health framework and deliver a coherent continuum of prevention, treatment, and long-term support."

Journal • Review • Genetic Disorders • Obesity

TTo investigate the effect of pre-pregnancy Beinaglutide Injection on pregnancy outcomes in overweight/obese PCOS patients (ChiCTR) - P=N/A | N=50 | Not yet recruiting | Sponsor: Lishui People's Hospital; Lishui People's Hospital

New trial • Obesity • Polycystic Ovary Syndrome

Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. (PubMed, Endocrinol Diabetes Metab) - "GLP-1 RAs carry a slightly increased risk of pancreatitis, which is not significant when stratified by background medication use. Overall risk for pancreatic cancer was not observed, but a slight association was found when stratified with background medications. However, this difference is likely minimal, given the numerous studies excluded from the meta-analysis where both treatment arms had zero events."

Clinical • Journal • Retrospective data • Review • Oncology • Pancreatic Cancer • Pancreatitis • Solid Tumor

Efficacy and safety of beinaglutide with continuous subcutaneous infusion in newly diagnosed patients with type 2 diabetes: a randomized, control, open-labeled clinical trial. (PubMed, J Endocrinol Invest) - P4 | "Adding CSGI to CSII therapy significantly led to significant weight loss and glycemic control in new diagnosed T2D patients. This combined approach shows promise but needs more research."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China. (PubMed, Diabetes Obes Metab) - "GLP-1 RA or GIP/GLP-1RA are not cost-effective for obesity treatment in China currently. Nevertheless, semaglutide exhibits relatively favourable economic potential across multiple subgroups."

HEOR • Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Successful outcome of assisted reproductive technology in women with polycystic ovary syndrome combined with empty follicle syndrome: A case report. (PubMed, Medicine (Baltimore)) - "Multiple complex mechanisms may be involved in the development of EFS, and preconditioning and individualized treatment protocols are essential for improving outcomes in patients with EFS. Our treatment protocol provides some reference basis for the treatment of EFS."

Journal • Infertility • Obesity • Polycystic Ovary Syndrome • Sexual Disorders

Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis. (PubMed, World J Diabetes) - "Short-term data from RCTs suggested that beinaglutide causes modest benefits in reducing body weight, BMI, and WC, with no significant difference in glycemic and other metabolic endpoints compared to the control arm. Safety data were consistent with those of the other drugs in the glucagon-like polypeptide-1 receptor agonist class. Larger RCTs are warranted to prove the longer-term metabolic benefits of beinaglutide."

Journal • Retrospective data • Diabetes • Fatigue • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Pain • Type 2 Diabetes Mellitus

Effects of beinaglutide on visceral fat area and gut microbiota in obesity. (PubMed, Eur J Med Res) - "Our findings provide insights into the mechanisms by which beinaglutide aids weight loss, particularly via modulating the gut microbiota."

Journal • Dyslipidemia • Gastrointestinal Disorder • Genetic Disorders • Infectious Disease • Inflammation • Metabolic Disorders • Obesity • CRP

Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients (clinicaltrials.gov) - P=N/A | N=115 | Recruiting | Sponsor: Beijing Hospital | Unknown status ➔ Recruiting | N=260 ➔ 115 | Trial completion date: Dec 2021 ➔ Dec 2025 | Trial primary completion date: Jun 2021 ➔ Sep 2025

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The effects of Beinaglutide on obesity and related factors: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Expert Rev Endocrinol Metab) - "In addition, body weight loss was greater in doses < 0.4 mg compared to doses ≥ 0.4 mg. The results of this meta-analysis show that Beinaglutide is effective in reducing parameters related to obesity, TG as well as SBP."

Journal • Retrospective data • Review • Genetic Disorders • Infectious Disease • Obesity

A randomized controlled study comparing the clinical pregnancy rates of Beinaglutide Injection combined with metformin and metformin monotherapy in overweight/obese patients with polycystic ovary syndrome (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine; Shanghai First Maternity and Infant Hospital, Tongji University Sc

New P4 trial • Obesity • Polycystic Ovary Syndrome

The effect of beinaglutide as an glucagon-like peptide-1 receptor agonists on cardiometabolic factors: a systematic review and meta-analysis. (PubMed, Diabetol Metab Syndr) - "The results of this meta-analysis show that Beinaglutide is effective in reducing factors related to obesity, TG as wll as SBP, especially with longer interventions and lower doses."

Journal • Retrospective data • Genetic Disorders • Infectious Disease • Obesity

Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity (clinicaltrials.gov) - P=N/A | N=392 | Not yet recruiting | Sponsor: Peking University Third Hospital

New trial • Genetic Disorders • Infertility • Obesity • Polycystic Ovary Syndrome • Sexual Disorders

An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review. (PubMed, Diabetes Obes Metab) - "Semaglutide and beinaglutide biosimilars are currently under investigation as well. With the growing popularity of GLP-1 RAs, accessibility and affordability remain a challenge as monthly costs without insurance for liraglutide, semaglutide and tirzepatide are $1418, $892, and $974 respectively...Preliminary results from liraglutide biosimilars are promising, and several semaglutide biosimilars are currently being investigated. Future research should focus on conducting comparative head-to-head trials to determine the clinical outcomes between biosimilars and reference products."

Journal • Review • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysis. (PubMed, BMJ Open) - "Implementation of NDPN and NCDP had successfully cut-off the price of novel hypoglycaemic drugs and significantly increased their utilisation. In the future, the government needs to control pharmaceutical expenses more strictly while ensuring the rational use of the drugs."

Journal • Diabetes • Endocrine Disorders • Metabolic Disorders

Comparison of the effects of benaglutide or metformin treatment on endocrine metabolism and pregnancy in overweight/obese patients with polycystic ovary syndrome (ChiCTR) - P=N/A | N=154 | Recruiting | Sponsor: The Third Affiliated Hospital of Guangzhou Medical University; The Third Affiliated Hospital of Guangzhou Medical University

New trial • Obesity • Polycystic Ovary Syndrome

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. (PubMed, Metabolism) - "Retatrutide (both doses) and tirzepatide exhibited superior efficacy compared to other GLP-1 receptor agonists and polyagonists in reducing body weight and waist circumference. Patients without T2DM, those with a high BMI, and individuals undergoing longer treatment cycles demonstrated significantly greater weight loss and reductions in waist circumference. Dual or triple receptor agonists (GLP-1 plus glucose-dependent insulinotropic polypeptide and/or Glucagon receptor) are more effective for weight loss than GLP-1 receptor agonists."

Journal • Retrospective data • Review • Diabetes • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial. (PubMed, Front Pharmacol) - "The safety profile and pharmacokinetic properties support further development and clinical applications of beinaglutide as an anti-obesity drug. [https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000BPEI&selectaction=Edit&uid=U00050YQ&ts=2&cx=wy0ioj]."

Journal • P1 data • PK/PD data • Genetic Disorders • Obesity • Type 2 Diabetes Mellitus

Metabolomics and molecular docking-directed anti-obesity study of the ethanol extract from Gynostemma pentaphyllum (Thunb.) Makino. (PubMed, J Ethnopharmacol) - "The extract of G. pentaphyllum can inhibit the absorption of tryptophan and its conversion to 5-HT through the Slc6a19/Tph1 pathway, upregulating the expression of Ucp1, thereby promoting thermogenesis in brown adipose tissue, facilitating weight loss, and mitigating symptoms of fatty liver. Triterpenoids such as Araliasaponin I, identified in GPE, could be the potential inhibitor of Tph1 and responsible for the anti-obesity activities."

Journal • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Obesity • SLC6A19

Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus. (PubMed, Risk Manag Healthc Policy) - "The final assessment result scores from highest to lowest were semaglutide (71.5 points), dulaglutide (68.9 points), liraglutide (68.7 points), exenatide (62.5 points), lixisenatide (59.9 points), polyethylene glycol loxenatide (55.9 points), and benaglutide (45.1 points). When a healthcare organization introduces GLP-1RAs to their hospital, they can refer to the assessment results and use the top three recommended medications: semaglutide, dulaglutide, and liraglutide."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus